Second Phase III study ESTABLISHes Trius antibiotic efficacy
This article was originally published in Scrip
Now that a second set of Phase III data show that Trius Therapeutics' lower-dose antibiotic tedizolid is non-inferior to Pfizer's Zyvox (linezolid), the San Diego-based company is preparing to file applications for US and EU marketing approval within the next year.
You may also be interested in...
Kynmobi is an important approval for parent company Sumitomo Dainippon ahead of the loss of exclusivity for Latuda. Sunovion hopes to launch after COVID-19 social distancing requirements ease.
Private Company Edition: Atea and Phlow receive big money for big COVID-19 problems – treatments and manufacturing capacity. Also, Cowen raises a $493m fund and antifungal developer Amplyx increases series C round to $90m, among other recent VC deals.
Public Company Edition: Moderna leveraged its all-time high stock price to raise $1.34bn on the same day it reported data from a Phase I trial of its COVID-19 vaccine. Several other companies also took advantage of biopharma’s rising value.